



ATTORNEYS AT LAW



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbalo
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Donald J. Featherstone
Lawrence B. Bugaisky
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Heidi L. Kraus
Albert L. Ferro*
Donald R. Banowitz
Peter A. Jackman
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaston
Kimberly N. Reddick
Theodore A. Wood
Elizabeth J. Haanes

Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhuier
Rae Lynn Prengaman
Jane Shershenovich*
George S. Bardmeser
Daniel A. Klein*
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller*
LuAnne M. DeSantis
John J. Figueiroa
Ann E. Summerfield
Tiera S. Coston
Aric W. Ledford*
Jessica L. Parezo
Timothy A. Doyle*

Gaby L. Longsworth*
Nicole D. Dretar*
Ted J. Ebersole
Jyoti C. Iyer*
Laura A. Vogel

Registered Patent Agents*

Karen R. Markowicz
Nancy J. Leith
Helene C. Carlson
Matthew J. Dowd
Aaron L. Schwartz
Katrina Y. Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford

Michelle K. Holoubek
Robert H. DeSelms
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse

Of Counsel
Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

June 8, 2004

WRITER'S DIRECT NUMBER:
(202) 772-8834

INTERNET ADDRESS:
BHAANES@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1646

Re: U.S. Utility Patent Application
Application No. 10/005,842; Filed: December 7, 2001
For: **Death Domain Containing Receptor 5**
Inventor: NI *et al.*
Our Ref: 1488.131000A/EKS/EJH

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Fourth Supplemental Information Disclosure Statement;
2. PTO-1449 (19 pages) citing sixty-four (64) documents;
3. Fee Transmittal (PTO/SB/17);
4. Credit Card Payment Form; and
5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
June 8, 2004
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Elizabeth J. Haanes, Ph.D.
Attorney for Applicant
Registration No. 42,613

EJH/M-M:amr
273674.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ni *et al.*

Appl. No.: 10/005,842

Filed: December 7, 2001

For: Death Domain Containing Receptor 5

Confirmation No.: 4105

Art Unit: 1646

Examiner: Kaufman, Claire, M.

Atty. Docket: 1488.131000A/EKS/EJH/M-M

Fourth Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fourth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Third Supplemental Information Disclosure Statement filed on May 30, 2003, in connection with the above-captioned application.

Copies of the cited documents were cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/042,583, filed March 17, 1998, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of the documents are not attached. 37 C.F.R. § 1.98(d).

The Examiner is referred to the following related, co-pending patent applications:

U.S. Patent Application No. 10/648,825, filed August 27, 2003, inventors Ni et al., cited

as Document AR33;

06/09/2004 HUUONG1 00000090 10005842

01 FC:1806

180.00 OP

U.S. Patent Application No. 10/774,622, filed February 10, 2004, inventors Ni *et al.*, cited as Document AS33.

The Examiner's attention is also directed to the following recently issued U.S. Patent directed to related subject matter: U.S. Patent No. 6,743,625 issued June 1, 2004, and cited as document AE2.

The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to this application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Fourth Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date and before the mailing date of a Final Rejection, or Notice of Allowance. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Elizabeth J. Haanes, Ph.D.
Attorney for Applicants
Registration No. 42,613

Date:

June 8, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL

for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00)



Complete if Known

Application Number	10/005,842
Filing Date	December 7, 2001
First Named Inventor	Jian NI
Examiner Name	Kaufman, Claire M.
Art Unit	1646
Attorney Docket No.	1488.131000A/EKS/EJH

METHOD OF PAYMENT (check all that apply)

 Check Credit card Money Order Other** None

 **Charge any deficiencies or credit any overpayments in Deposit Account: *The fees to Deposit Acct. No. 19-0036*

Deposit Account Number **19-0036**
 Deposit Account Name **Sterne, Kessler, Goldstein & Fox P.L.L.C.**

The Director is authorized to: (check all that apply)

- Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) or any underpayment of fee(s)
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1)		(\$)	0,00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Independent Claims	Multiple Dependent	Extra Claims	Fee from below	Fee Paid
			- 20	= <input type="text"/> X <input type="text"/> = <input type="text"/>	
			- 3	= <input type="text"/> X <input type="text"/> = <input type="text"/>	

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1202 18	2202 9	Claims in excess of 20	
1201 86	2201 43	Independent claims in excess of 3	
1203 290	2203 145	Multiple dependent claim, if not paid	
1204 86	2204 43	** Reissue independent claims over original patent	
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)		(\$)	0,00

**or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	180,00
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	
Other fee (specify)			
*Reduced by Basic Filing Fee Paid		SUBTOTAL (3)	(\$)
			180,00

(Complete if applicable)


Name (Print/Type)	Elizabeth J. Haanes, Ph.D.	Registration No. (Attorney/Agent)	42,613	Telephone	(202) 371-2600
Signature	<i>Elizabeth J. Haanes</i>	Date			June 8, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FORM PTO-1449

FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT & TRADEMARKSCITY, DOCKET NO.
1468.131000AEKS/EJH/M-MAPPLICATION NO.
10/005,842

FIRST NAMED INVENTOR

Ni et al.

FILING DATE

December 7, 2001

ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB2	6,743,625	06/01/2004	Ni et al.			06/06/2001
	AC2	6,461,823	10/08/2002	Ni et al.			11/24/1999
	AD2	6,342,363	01/29/2002	Ni et al.			01/27/1998
	AE2	6,433,147	08/13/2002	Ni et al.			05/05/2000
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL4	WO 98/41629 A2 & A3	09/24/1998	WIPO			Yes
	AM4	EP 1 181 319 A0	12/07/2000	Europe			No
	AN4	EP 1 192 185 A0	12/14/2000	Europe			Yes
	AO4	EP 1 287 035 A1	03/05/2003	Europe			No
	AP						Yes
							No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>15</u>	Allison, J., et al., "Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts," <i>Proc. Natl. Acad. Sci. USA</i> 94:3943-3947, National Academy Press (April 1997)
AS	<u>15</u>	Allison, J., and Strasser, A., "Mechanisms of β cell death in diabetes: A minor role for CD95," <i>Proc. Natl. Acad. Sci. USA</i> 95:13818-13822, National Academy Press (November 1998)
AT	<u>15</u>	Bodmer, J.-L., et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)," <i>Immunity</i> 6:79-88, Cell Press (January 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000AEKS/EJH/M-MAPPLICATION NO.
10/005,842FIRST NAMED INVENTOR
Ni et al.FILING DATE
December 7, 2001ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>16</u>	Boldin, M.P., et al., "A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain," <i>J. Biol. Chem.</i> 270:7795-7798, American Society for Biochemistry and Molecular Biology, Inc. (1995)
AS	<u>16</u>	Chicheportiche, Y., et al., "TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis," <i>J. Biol. Chem.</i> 272:32401-32410, American Society for Biochemistry and Molecular Biology, Inc. (December 1997)
AT	<u>16</u>	Chinnaiyan, A.M., et al., "FADD, a Novel Death Domain-Containing Protein, Interacts with the Death Domain of Fas and Initiates Apoptosis," <i>Cell</i> 81:505-512, Cell Press (1995)

EXAMINER _____ DATE CONSIDERED _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

JUN 08 2004

FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000AEKS/EJH/M-MAPPLICATION NO.
10/005,842FIRST NAMED INVENTOR
Ni et al.FILING DATE
December 7, 2001ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	17	Clerici, M., et al., "Type 1 and Type 2 Cytokines in HIV Infection - A Possible Role in Apoptosis and Disease Progression," <i>Ann. Med.</i> 29:185-188, Finnish Medical Society DUODECIM (June 1997)
AS	17	Degli-Esposti, M.A., et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," <i>J. Exp. Med.</i> 186:1165-1170, Rockefeller University Press (October 1997)
AT	17	Degli-Esposti, M.A., et al., "The Novel Receptor TRAIL-R4 Induces NF- κ B and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain," <i>Immunity</i> 7:813-820, Cell Press (December 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

JUN 08 2004

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1488.131000AEKS/EJH/M-MAPPLICATION NO.
10/005,842FIRST NAMED INVENTOR
Ni et al.FILING DATE
December 7, 2001ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>18</u>	Duan, H. and Dixit, V.M., "RAIDD is a new 'death' adaptor molecule," <i>Nature</i> 385:86-89, Macmillan Publishers, Ltd. (January 1997)
AS	<u>18</u>	Frankfurt, O.S., et al., "Protection from Apoptotic Cell Death by Interleukin-4 is Increased in Previously Treated Chronic Lymphocytic Leukemia Patients," <i>Leuk. Res.</i> 21:9-16, Elsevier Science, Ltd (January 1997)
AT	<u>18</u>	Gooch, J.L., et al., "Interleukin 4 Inhibits Growth and Induces Apoptosis in Human Breast Cancer Cells," <i>Cancer Res.</i> 58:4199-4205, American Association for Cancer Research (September 1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**



ATTY. DOCKET NO.
1488.131000AEKS/EJH/M-M

APPLICATION NO.
10/005,842

FIRST NAMED INVENTOR
Ni et al.

FILING DATE
December 7, 2001

ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	19	Grell, M., et al., "Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF," <i>EMBO J.</i> 18:3034-3043, Oxford University Press (June 1999)
	AS	19	Hardiman, G., et al., "Genetic Structure and Chromosomal Mapping of MyD88," <i>Genomics</i> 45:332-339, Academic Press (October 1997)
	AT	19	Hildeman, D.A., et al., "Activated T Cell Death In Vivo Mediated by Proapoptotic Bcl-2 Family Member Bim," <i>Immunity</i> 16:759-767, Cell Press (June 2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449		ATTY. DOCKET NO. 51488.131000AEKS/EJH/M-M		APPLICATION NO. 10/005,842	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		FIRST NAMED INVENTOR Ni et al.			
		FILING DATE December 7, 2001		ART UNIT 1646	



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>20</u>	Hill, M.E., et al., "Prognostic Significance of BCL-2 Expression and <i>bcl-2</i> Major Breakpoint Region Rearrangement in Diffuse Large Cell Non-Hodgkin's Lymphoma: A British National Lymphoma Investigation Study," <i>Blood</i> 88:1046-105, American Society of Hematology (August 1996)
AS	<u>20</u>	Ho, Y.S., et al., "Brain acetylhydrolase that inactivates platelet-activating factor is a G-protein-like trimer," <i>Nature</i> 385:89-93, Macmillan Publishers, Ltd. (January 1997)
AT	<u>20</u>	Hofmann, K., and Bucher, P., "The CARD domain: a new apoptotic signalling motif," <i>Trends Biochem. Sci.</i> 22:155-156, Elsevier Science, Ltd. (May 1997)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**



ATTY. DOCKET NO.
1488.131000AEKS/EJH/M-M

APPLICATION NO.
10/005,842

FIRST NAMED INVENTOR
Ni et al.

FILING DATE
December 7, 2001

ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>21</u>	Horigome, A., et al., "Tacrolimus-induced apoptosis and its prevention by interleukins in mitogen-activated human peripheral-blood mononuclear cells," <i>Immunopharmacology</i> 39:21-30, Elsevier Science B.V. (March 1998)
AS	<u>21</u>	Hsu, H., et al., "TRADD-TRAF2 and TRADD-FADD Interactions Define Two Distinct TNF Receptor 1 Signal Transduction Pathways," <i>Cell</i> 84:299-308, Cell Press (January 1996)
AT	<u>21</u>	Huang, D.C.S., et al., "Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x _L ," <i>Proc. Natl. Acad. Sci. USA</i> 96:14871-14876, National Academy Press (December 1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
13488.131000AEKS/EJH/M-M
FIRST NAMED INVENTOR
Ni et al.

APPLICATION NO.
10/005,842

FILING DATE
December 7, 2001

ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>22</u>	Huang, D.C.S., et al., "Bcl-2, Bcl-x _L and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death," <i>Oncogene</i> 14:405-414, Stockton Press (January 1997)
AS	<u>22</u>	Irmier, M., et al., "Direct physical interaction between the <i>Caenorhabditis elegans</i> 'death proteins' CED-3 and CED-4," <i>FEBS Lett.</i> 406:189-190, Elsevier Science B.V. (April 1997)
AT	<u>22</u>	Irmier, M., et al., "Inhibition of death receptor signals by cellular FLIP," <i>Nature</i> 388:190-195, Macmillan Publishers, Ltd. (July 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

		ATTY. DOCKET NO. 1488.131000AEKS/EJH/M-M	APPLICATION NO. 10/005,842
		FIRST NAMED INVENTOR Ni et al.	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		FILING DATE December 7, 2001	ART UNIT 1646

O I P E
JUN 08 2004
U. S. PATENT AND TRADEMARK OFFICE

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>23</u>	Karin, M., and Lin, A., "NF-κB at the crossroads of life and death," <i>Nat. Immunol.</i> 3:221-227, Nature Publishing Group (March 2002)
AS	<u>23</u>	Kelliher, M.A., et al., "The Death Domain Kinase RIP Mediates the TNF-Induced NF-κB Signal," <i>Immunity</i> 8:297-303, Cell Press (March 1998)
AT	<u>23</u>	Lindner, H., et al., "Peripheral Blood Mononuclear Cells Induce Programmed Cell Death in Human Endothelial Cells and May Prevent Repair: Role of Cytokines," <i>Blood</i> 89:1931-1938, American Society of Hematology (March 1997)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

JUN 08 2004

ATTY. DOCKET NO.
488.131000AEKS/EJH/M-M
FIRST NAMED INVENTOR
Ni et al.

APPLICATION NO.
10/005,842

FILING DATE
December 7, 2001

ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>24</u>	Lotem, J., and Sachs, L., "Hematopoietic Cytokines Inhibit Apoptosis Induced by Transforming Growth Factor β 1 and Cancer Chemotherapy Compounds in Myeloid Leukemic Cells," <i>Blood</i> 80:1750-1757, American Society of Hematology (1992)
AS	<u>24</u>	Lotem, J., and Sachs, L., "Interferon- γ inhibits apoptosis induced by wild-type p53, cytotoxic anti-cancer agents and viability factor deprivation in myeloid cells," <i>Leukemia</i> 9:685-692, Stockton Press (1995)
AT	<u>24</u>	MacFarlane, M., et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL," <i>J. Biol. Chem.</i> 272:25417-25420, American Society for Biochemistry and Molecular Biology, Inc. (October 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449		JUN 08 2004 U.S. PATENT & TRADEMARK OFFICE		ATTY. DOCKET NO. 1438.131000AEKS/EJH/M-M	APPLICATION NO. 10/005,842
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				FIRST NAMED INVENTOR <i>et al.</i>	
				FILING DATE December 7, 2001	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>25</u>	Muzio, M., <i>et al.</i> , "FLICE, a Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex," <i>Cell</i> 85:817-827, Cell Press (June 1996)
AS	<u>25</u>	Muzio, M., <i>et al.</i> , "IRAK (Pelle) Family Member IRAK-2 and MyD88 as Proximal Mediators of IL-1 Signaling," <i>Science</i> 278:1612-1615, American Association for the Advancement of Science (November 1997)
AT	<u>25</u>	Newton, K., <i>et al.</i> , "A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes," <i>EMBO J.</i> 17:706-718, Oxford University Press (February 1998)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

		ATTY. DOCKET NO. 1488.131000AEKS/EJH/M-M	APPLICATION NO. 10/005,842
FORM PTO-1449 FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		FIRST NAMED INVENTOR Ni et al.	
		FILING DATE December 7, 2001	ART UNIT 1646



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>26</u>	Newton, K., et al., "FADD/MORT1 regulates the pre-TCR checkpoint and can function as a tumour suppressor," <i>EMBO J.</i> 19:931-941, Oxford University Press (March 2000)
AS	<u>26</u>	Newton, K., et al., "Effects of a dominant interfering mutant of FADD on signal transduction in activated T cells," <i>Curr. Biol.</i> 11:273-276, Elsevier Science, Ltd. (February 2001)
AT	<u>26</u>	Newton, K., and Strasser, A., "Ionizing Radiation and Chemotherapeutic Drugs Induce Apoptosis in Lymphocytes in the Absence of Fas or FACC/MORT1 Signaling: Implications for Cancer Therapy," <i>J. Exp. Med.</i> 191:195-200, Rockefeller University Press (January 2000)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449

FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000AEKS/EJH/M-MAPPLICATION NO.
10/005,842

FIRST NAMED INVENTOR

Ni et al.

FILING DATE

December 7, 2001

ART UNIT

1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes
	AM						No
	AN						Yes
	AO						No
	AP						Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>27</u>	O'Conner, L., et al., "Fas, p53, and Apoptosis," <i>Science</i> 284:1431b, American Association for the Advancement of Science (May 1999)
AS	<u>27</u>	O'Conner, L., et al., "CD95 (Fas/APO-1) and p53 Signal Apoptosis Independently in Diverse Cell Types," <i>Cancer Res.</i> 60:1217-1220, American Association for Cancer Research (March 2000)
AT	<u>27</u>	Odaka, C., et al., "Immunosuppressant deoxyspergualin induces apoptotic cell death in dividing cells," <i>Immunol.</i> 95:370-376, Blackwell Science, Ltd. (November 1998)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**



ATTY. DOCKET NO.
1488.131000AEKS/EJH/M-M
FIRST NAMED INVENTOR
Ng et al.

APPLICATION NO.
10/005,842

FILING DATE
December 7, 2001

ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes
	AM						No
	AN						Yes
	AO						No
	AP						Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>28</u>	Pan, G., et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," <i>FEBS Lett.</i> 424:41-45, Elsevier Science B.V. (March 1998)
	AS	<u>28</u>	Screaton, G.R., et al., "LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing," <i>Proc. Natl. Acad. Sci. USA</i> 94:4615-4619, National Academy Press (April 1997)
	AT	<u>28</u>	Shadmehr, R., and Holcomb, H.H., "Neural Correlates of Motor Memory Consolidation," <i>Science</i> 277:821-825, American Association for the Advancement of Science (August 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

JUN 08 2004

ATTY. DOCKET NO.

10488.131000AEKS/EJH/M-M

APPLICATION NO.

10/005,842

FIRST NAMED INVENTOR

Ski et al.

FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTFILING DATE
December 7, 2001ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	29	Simonitsch, I., and Krupitza, G., "Autocrine self-elimination of cultured ovarian cancer cells by tumour necrosis factor α (TNF- α)," <i>Br. J. Cancer</i> 78:862-870, Nature Publishing Group on behalf of Cancer Research, UK (October 1998)
AS	29	Smith, K.G.C., et al., "CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphadenopathy or autoimmune disease," <i>EMBO J.</i> 15:5167-5176, Oxford University Press (October 1996)
AT	29	Strasser, A., et al., "Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis," <i>EMBO J.</i> 14:6136-6147, Oxford University Press (1995)

EXAMINER _____ DATE CONSIDERED _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

JUN 08 2004

PATENT & TRADEMARK OFFICE

ATTY. DOCKET NO.
61488.131000AEKS/EJH/M-M
FIRST NAMED INVENTOR
Ni et al.

APPLICATION NO.
10/005,842

FILING DATE
December 7, 2001

ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>30</u>	Thome, M., et al., "Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors," <i>Nature</i> 386:517-521, Macmillan Publishers, Ltd. (April 1997)
AS	<u>30</u>	Villunger, A., et al., "Fas Ligand, Bcl-2, Granulocyte Colony-Stimulating Factor, and p38 Mitogen-activated Protein Kinase: Regulators of Distinct Cell Death and Survival Pathways in Granulocytes," <i>J. Exp. Med.</i> 192:647-657, Rockefeller University Press (September 2000)
AT	<u>30</u>	Villunger, A., et al., "Fas Ligand-Induced c-Jun Kinase Activation in Lymphoid Cells Requires Extensive Receptor Aggregation But Is Independent of DAXX, and Fas-Mediated Cell Death Does Not Involve DAXX, RIP, or RAIDD," <i>J. Immunol.</i> 165:1337-1343, American Association of Immunologists (August 2000)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT



ATTY. DOCKET NO.
1488.131000AEKS/EJH/M-M
FIRST NAMED INVENTOR
Li et al.

APPLICATION NO.
10/005,842

FILING DATE
December 7, 2001

ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes
	AM						No
	AN						Yes
	AO						No
	AP						Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


	AR	31	Walczak, H., et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," <i>EMBO J.</i> 16:5386-5397, Oxford University Press (September 1997)
	AS	31	Watanabe-Fukunaga, R., et al., "Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis," <i>Nature</i> 356:314-317, Macmillan Publishers, Ltd. (1992)
	AT	31	Wong, B.B., et al., "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells," <i>J. Biol. Chem.</i> 272:25190-25194, American Society for Biochemistry and Molecular Biology, Inc. (October 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTLATTY, DOCKET NO.
S-488.131000AEKS/EJH/M-MAPPLICATION NO.
10/005,842FIRST NAMED INVENTOR
Ni et al.FILING DATE
December 7, 2001ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>32</u>	Yoshida, T., et al., "Rapid B cell apoptosis induced by antigen receptor ligation does not require Fas (CD95/APO-1), the adaptor protein FADD/MORT1 or CrmA-sensitive caspases but is defective in both MRL-+/+ and MRL-lpr/lpr mice," <i>Int. Immunol.</i> 12:517-526, Japanese Society for Immunology (April 2000)
AS	<u>32</u>	Zou, W., et al., "Administration of Interleukin 13 to Simian Immunodeficiency Virus-Infected Macaques: Induction of Intestinal Epithelial Atrophy," <i>AIDS Res Hum Retroviruses</i> 14:775-793, Mary Ann Liebert, Inc. (June 1998)
AT	<u>32</u>	European Search Report for European Application No. EP 00 93 0329 mailed on February 6, 2004, Munich, Germany

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1488.131000AEKS/EJH/M-M
FIRST NAMED INVENTOR
Ni et al.

APPLICATION NO.
10/005,842

FILING DATE
December 7, 2001

ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	33	Copy of co-pending U.S. Application No. 10/648,825, inventors Ni et al., filed August 27, 2003
AS	33	Copy of co-pending U.S. Application No. 10/774,622, inventors Ni et al., filed February 10, 2004
AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.